Diomed (AMEX:DIO)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Diomed Charts. Click Here for more Diomed Charts.](/p.php?pid=staticchart&s=A%5EDIO&p=8&t=15)
Diomed Holdings, Inc. (AMEX: DIO), a leading developer and marketer of
minimally invasive medical technologies, including its patented
EndoVenous Laser Treatment (EVLTŪ) for
varicose veins, today announced that it will host a conference call to
review the company's second quarter ended June 30, 2007 financial
results.
The call will be conducted on Thursday, July 26, 2007, at 10:00 a.m.
(Eastern Time) and will be hosted by James A. Wylie, Jr., President and
Chief Executive Officer, and David B. Swank, Chief Financial Officer.
The company's financial results are scheduled to be released earlier
that day.
Interested parties may access the conference call by dialing 800.901.5217
(domestic) or 617.786.2964 (international), participant pass code
78617684. The call will also be available via web cast at www.diomedinc.com.
If you are unable to participate, an audio digital replay of the call
will be available from Thursday, July 26, 2007 12:00 p.m. Eastern Time,
until Thursday, August 2, 2007, 11:59 p.m. Eastern Time. The digital
replay can be accessed by dialing (domestic) or 617-801-6888
(international), using pass code 55922592. A web archive will also be
available during this time period at www.diomedinc.com.
About Diomed
Diomed develops and commercializes minimal and micro-invasive medical
procedures that use its proprietary laser technologies and disposable
products. Diomed's EVLT(R) laser vein ablation procedure is used in
varicose vein treatments. Diomed also provides photodynamic therapy
(PDT) for use in cancer treatments, and dental and general surgical
applications. The EVLT(R) procedure and the Company's related products
were cleared by the United States FDA in January of 2002. Along with
lasers and single-use procedure kits for its EVLT(R) laser vein
treatment, the Company provides its customers with state of the art
physician training and practice development support. Additional
information is available on the Company's website: www.evlt.com.
EVLT(R) is a registered trademark of Diomed Inc., Andover, MA.
Safe Harbor statements under the Private Securities Litigation Reform
Act of 1995: Statements in this news release looking forward in time
involve risks and uncertainties, including the risks associated with
trends in the products markets, reliance on third party distributors in
various countries outside the United States, reoccurring orders under
OEM contracts, market acceptance risks, technical development risks and
other risk factors. These statements relate to our future plans,
objectives, expectations and intentions. These statements may be
identified by the use of words such as "may," "will," "should,"
"potential," "expects," "anticipates," "intends," "plans," "believes"
and similar expressions. These statements are based on our current
beliefs, expectations and assumptions and are subject to a number of
risks and uncertainties. Our actual results could differ materially from
those discussed in these statements. Our Annual Report on Form SEC
10-KSB (the "Annual Report") contains a discussion of certain of the
risks and uncertainties that affect our business. We refer you to the
"Risk Factors" on pages 19 through 34 of the Annual Report for a
discussion of certain risks, including those relating to our business as
a medical device company without a significant operating record and with
operating losses, our risks relating to our commercialization of our
current and future products and applications and risks relating to our
common stock and its market value. Diomed disclaims any obligation or
duty to update or correct any of its forward-looking statements.